Assignee
C4 THERAPEUTICS INC
US·36 granted patents·26 pending applications·243 citations·filing 2018–2025
Top patents by PatentIndex Score
62 records- 0197US11584748B2Spirocyclic compoundsC4 THERAPEUTICS INC·Filed 2020·Granted Feb 21, 2023·11 cites·11 claims
- 0297US11407732B1Tricyclic degraders of Ikaros and AiolosC4 THERAPEUTICS INC·Filed 2021·Granted Aug 9, 2022·10 cites·30 claims
- 0397US11185592B2Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Nov 30, 2021·20 cites·26 claims
- 0497US10660968B2Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Granted May 26, 2020·32 cites·35 claims
- 0596US11623929B2Spirocyclic compoundsC4 THERAPEUTICS INC·Filed 2020·Granted Apr 11, 2023·7 cites·20 claims
- 0696US11524949B2Degraders and Degrons for targeted protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Dec 13, 2022·7 cites·18 claims
- 0796US10905768B1Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Feb 2, 2021·31 cites·20 claims
- 0896US10849982B2C3-carbon linked glutarimide degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Granted Dec 1, 2020·43 cites·17 claims
- 0996US10646575B2Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Granted May 12, 2020·32 cites·28 claims
- 1095US12048747B2Substituted piperidine Degronimers for Target Protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Jul 30, 2024·4 cites·22 claims
- 1195US11673902B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2022·Granted Jun 13, 2023·3 cites·29 claims
- 1294US11459335B2N/O-linked Degrons and Degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2019·Granted Oct 4, 2022·8 cites·23 claims
- 1394US11254672B2Dihydrobenzimidazolones for medical treatmentC4 THERAPEUTICS INC·Filed 2020·Granted Feb 22, 2022·7 cites·22 claims
- 1493US12371442B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2023·Granted Jul 29, 2025·1 cites·28 claims
- 1593US11992531B2C3-carbon linked glutarimide degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted May 28, 2024·3 cites·31 claims
- 1693US11802131B2Glutarimides for medical treatmentC4 THERAPEUTICS INC·Filed 2020·Granted Oct 31, 2023·4 cites·9 claims
- 1793US11787802B2Dihydrobenzimidazolones for medical treatmentC4 THERAPEUTICS INC·Filed 2022·Granted Oct 17, 2023·3 cites·19 claims
- 1893US11691972B2Compounds for targeted degradation of BRD9C4 THERAPEUTICS INC·Filed 2021·Granted Jul 4, 2023·5 cites·10 claims
- 1992US11401256B2Dihydroquinolinones for medical treatmentC4 THERAPEUTICS INC·Filed 2020·Granted Aug 2, 2022·5 cites·26 claims
- 2090US12048748B2Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2021·Granted Jul 30, 2024·1 cites·21 claims
- 2190US2026042782A1Isoindolinone and indazole compounds for the degradation of egfrC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2289US12157735B2Compounds for targeted degradation of BRD9C4 THERAPEUTICS INC·Filed 2022·Granted Dec 3, 2024·1 cites·23 claims
- 2388US12049464B2Compounds for targeted degradation of BRD9C4 THERAPEUTICS INC·Filed 2022·Granted Jul 30, 2024·1 cites·11 claims
- 2487US12180225B2N/O-linked degrons and degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2022·Granted Dec 31, 2024·1 cites·19 claims
- 2587US12091397B2Dihydroquinolinones for medical treatmentC4 THERAPEUTICS INC·Filed 2022·Granted Sep 17, 2024·1 cites·13 claims
- 2685US12076405B2Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2021·Granted Sep 3, 2024·1 cites·20 claims
- 2783US2026015362A1N/o-linked degrons and degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2883US2025057957A1Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2983US2025121069A1Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3081US12486253B2Therapeutics for the degradation of mutant BRAFC4 THERAPEUTICS INC·Filed 2024·Granted Dec 2, 2025·0 cites·4 claims
- 3181US11753397B2Cereblon binders for the degradation of ikarosC4 THERAPEUTICS INC·Filed 2020·Granted Sep 12, 2023·1 cites·19 claims
- 3281US2025084081A1Compounds for targeted degradation of brd9C4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3380US12486290B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2025·Granted Dec 2, 2025·0 cites·30 claims
- 3480US2025127903A1Substituted piperidine degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3579US12421220B2Bicyclic-substituted glutarimide cereblon bindersC4 THERAPEUTICS INC·Filed 2024·Granted Sep 23, 2025·0 cites·26 claims
- 3679US12365681B2Dihydrobenzimidazolones for medical treatmentC4 THERAPEUTICS INC·Filed 2023·Granted Jul 22, 2025·0 cites·16 claims
- 3779US12227504B2Spirocyclic compoundsC4 THERAPEUTICS INC·Filed 2023·Granted Feb 18, 2025·0 cites·13 claims
- 3879US2025382285A1Bicyclic-substituted glutarimide cereblon bindersC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3979US2025368631A1Bicyclic-substituted glutarimide cereblon bindersC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4077US2025084055A1Dihydroquinolinones for medical treatmentC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4176US12441740B2N/O-linked degrons and degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2024·Granted Oct 14, 2025·0 cites·19 claims
- 4273US2026015338A1Targeted protein degradationC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4371US2024018156A1Spirocyclic compoundsC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4470US12570626B2Degraders and degrons for targeted protein degradationC4 THERAPEUTICS INC·Filed 2022·Granted Mar 10, 2026·0 cites·16 claims
- 4570US2025282780A1Spirocyclic compoundsC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4670US2024199581A1Therapeutics for the degradation of mutant brafC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4769US2024199638A1Glutarimides for medical treatmentC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4867US2023082430A1Tricyclic degraders of ikaros and aiolosC4 THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4963US2024158418A1EGFR Degraders to Treat Cancer Metastasis to the Brain or CNSC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 5063US2025121070A1Compounds for the targeted degradation of smarca2C4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
Showing the top 50 of 62 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →